Compare Illumina, Inc. (ILMN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Schlumberger NV — how do they compare? Illumina, Inc. trades at $189.49 (market cap $27.94B), while Schlumberger NV trades at $46.39 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 2.5× Illumina, Inc.'s market cap, and Schlumberger NV pays a 2.54% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SLB | |
|---|---|---|
Market Cap | $27.94B | $69.36B |
Sector | Health | Energy |
52-Week High | $194.33 | $58.01 |
52-Week Low | $91.00 | $31.72 |
Enterprise Value | $29.33B | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
SLB trades at $46.67, down 0.68% on the day, with a bearish technical signal from moving averages. The company reported revenue of $35.71 billion in 2025 with a net income margin of 9.26%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights strategic alliances for data center power solutions and new contract wins, signaling growth in digital and offshore segments.
The outlook is supported by strong analyst consensus with a $62.83 price target and 84.85% buy ratings, but risks include oil price volatility and execution challenges. The stock offers value with a P/E of 20.7 and ROE of 14.57%, though margin compression from 2024 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
